Skip to main content

For US Healthcare Professionals only

SOLIQUA® 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL & 33 mcg/mL logo
Home
What Is SOLIQUA 100/33?
Dosing

Patient Uncontrolled on Basal Insulin for Soliqua® 100/33 (Insulin Glargine and Lixisenatide) Injection

LixiLan-L Study Design and Limitations

Designed to Evaluate the Efficacy and Safety of SOLIQUA 100/33 vs Lantus as an Adjunct to Diet and Exercise1

In the LixiLan-L pivotal trial, a total of 736 patients with T2DM participated in a randomized, 30-week, open-label, multicenter study to evaluate the efficacy and safety of SOLIQUA 100/33 compared to Lantus.1

Diagram showing A1C levels: Lantus titration 8.5% (Week -6), randomization 8.1% (Week 0), and treatment 7.5% Lantus, 6.9% Soliqua (Week 30) in LixiLan‑L Pivotal Study. The limitations include that the study is not designed or powered to detect differences between treatments within this subgroup; the difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.
  • Adults with T2DM, mean age 60 years, uncontrolled on a stable daily basal insulin dose ±1 or 2 OADs for ≥6 months (A1C of 7.5%-10%; FPG ≤180 mg/dL) were screened.1
  • Eligible patients (N=1018) were enrolled in a 6-week run-in period where they remained on or were switched to Lantus if on another basal insulin, and had their dose titrated/stabilized while continuing on metformin (if previously taken). Any other OADs were discontinued.1
  • Patients inadequately controlled at the end of the run-in period (n=736; A1C between 7% and 10%; FPG ≤140 mg/dL) and on an insulin glargine dose of 20 to 50 Units (mean dose of 35 Units) were randomized to either SOLIQUA 100/33 (n=367) or Lantus (n=369).1
  • The primary endpoint was change from baseline A1C at Week 30.1
  • The maximum allowable insulin glargine dose was 60 Units for both treatment groups.1
  • The trial was designed to show the contribution of the GLP-1 RA component to glycemic lowering, and the insulin glargine dose and the dosing algorithm were selected to isolate the effect of the GLP-1 RA component.1

Post Hoc Analysis Study Design

This post hoc analysis used patient-level data from patients aged ≥65 years from the phase III LixiLan-O and LixiLan-L studies, which compared iGlarLixi with iGlar and lixisenatide (LixiLan-O only). Efficacy endpoints were changes in glycated hemoglobin A1C, fasting plasma glucose, postprandial glucose, weight, and achievement of A1C <7.0 % (53 mmol /mol). Safety measures included incidence of documented symptomatic hypoglycemia (defined as typical symptoms of hypoglycemia plus self-measured plasma glucose ≤70 mg/dL [3 .9 mmol /L]), severe hypoglycemia (requiring assistance of another person), and incidence of gastrointestinal adverse events.2

Post Hoc Analysis Limitations

This study was not designed or powered to detect differences between treatments within this subgroup. The difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.1,2

LixiLan-L Pivotal Data

SOLIQUA 100/33 Demonstrated ~2x Greater A1C Reduction vs Lantus®1

Bar graph with Soliqua 100/33 at 6.9% and Lantus at 7.5% A1C reduction from a mean baseline of 8.1% in a LixiLan-L Pivotal study. The limitation includes that the difference in effect observed in the trial may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.

Analysis limitations: The difference in effect observed in the trial may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.1

1.1% mean reduction in A1C from baseline for SOLIQUA 100/33 vs 0.6% for Lantus.1

Portrait of a woman with gray hair wearing a patterned shirt, framed in a purple circle.

Learn About Maria
Portrait of a smiling woman with curly hair and earrings, framed in a purple circle.

Learn About Lidia
Portrait of a woman with gray hair wearing a patterned shirt, framed in a purple circle.

Not actual patient or profile. Individual results may vary.

 
Maria, 70

Retired

Current treatment

  • Metformin 1000 mg BID
  • Insulin glargine U-100, 40 Units QHS
  • Empagliflozin 25 mg QD

  

  •  Lisinopril 20 mg QD
  • Atorvastatin 10 mg QD

Physical & lab evaluation

  • A1C: 8.9%
  • FPG: 128 mg/dL
  • PPG: 266 mg/dL
  • BMI: 29 kg/m2

Patient History

  • Duration of diabetes: 11 years
  • High blood glucose levels at 1-2 points during the day (~2 hours after meal); levels also slightly elevated at night (~9 pm)
  • Previous episodes of hypoglycemia
  • Previous nonadherence due to missed doses and multiple medications
  • Concerned about co-pays/out-of-pocket costs

Insurance

  • Medicare Advantage Prescription Drug Plan

   

LixiLan-L Pivotal Study

LixiLan-L Post Hoc Subgroup Analysis

A ~2.3X Greater A1C Reduction Was Observed With Soliqua 100/33 In Older Adults (≥65) With T2Dm1,2

Chart showing A1C reductions from baseline (8.1%) to Week 30 with Soliqua 100/33 (-1.11%) and Lantus (-0.48%) in LixiLan-L Post Hoc Subgroup Analysis Study. The limitations include that the study is not designed or powered to detect differences between treatments within this subgroup; the difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.

Analysis limitations: This study was not designed or powered to detect differences between treatments within this subgroup. The difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.1,2

LixiLan-L Post Hoc Subgroup Analysis

~2.5x More Older Adults (≥65) With T2DM Were Shown to Achieve Their A1C Goal When Taking SOLIQUA 100/332

Chart showing percentage of patients achieving A1C <7% at Week 30: 51.8% for Soliqua 100/33 (n=110) and 21.0% for Lantus (n=119) in LixiLan-L Post Hoc Subgroup Analysis Study. The limitations include that the study is not designed or powered to detect differences between treatments within this subgroup; the difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.

Analysis limitations: This study was not designed or powered to detect differences between treatments within this subgroup. The difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.1,2

LixiLan-L Post Hoc Subgroup Analysis

Reduction in PPG Was ~4x Greater With SOLIQUA 100/33 Than Seen With Lantus in Older Adults (≥65) With T2DM2

Bar chart showing change in 2-hour PPG at Week 30: Soliqua 100/33 (n=110) at -94.4 mg/dL and Lantus (n=119) at -24.1 mg/dL in LixiLan-L Post Hoc Subgroup Analysis Study. The limitations include that the study is not designed or powered to detect differences between treatments within this subgroup; the difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.

Analysis limitations: This study was not designed or powered to detect differences between treatments within this subgroup. The difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.1,2

LixiLan-L Post Hoc Subgroup Analysis

Reduction in A1C Without Additional Weight Gain Was Observed in Older Adults (≥65) With T2DM Taking SOLIQUA 100/332

Chart showing change in body weight at Week 30: Soliqua 100/33 (n=110) at -1.2 kg and Lantus (n=119) at 0.6 kg in LixiLan-L Post Hoc Subgroup Analysis Study. The limitations include that the study is not designed or powered to detect differences between treatments within this subgroup; the difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.

Analysis limitations: This study was not designed or powered to detect differences between treatments within this subgroup. The difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.1,2

LixiLan-L Post Hoc Subgroup Analysis

Reduced Hypoglycemic Events Were Observed With SOLIQUA 100/33 vs Lantus2

Table showing hypoglycemia events over 30 weeks: Soliqua 2.84 vs. Lantus 4.91 (≥65 years), and Soliqua 3.12 vs. Lantus 3.88 (<65 years) in LixiLan-L Post Hoc Subgroup Analysis Study. The limitations include that the study is not designed or powered to detect differences between treatments within this subgroup; the difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.

Analysis limitations: This study was not designed or powered to detect differences between treatments within this subgroup. The difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.1,2

*Documented symptomatic hypoglycemia defined as typical symptoms of hypoglycemia accompanied by an SMPG value of ≤70 mg/dL.2

Hypoglycemia is the most common adverse event with insulin-containing therapy.1

  • From the pivotal trial data, severe symptomatic hypoglycemia for SOLIQUA 100/33 was 1.1% (4 out of 365 patients).1
    • Severe symptomatic hypoglycemia defined as an event requiring assistance of another person to actively administer carbohydrates, glucagon, or other resuscitative actions.1
Portrait of a smiling woman with curly hair and earrings, framed in a purple circle.

Not actual patient or profile. Individual results may vary.

Lidia, 46

Nurse

Current treatment

  • Metformin 1000 mg BID
  • Lantus 35 units QD

 

  • Olmesartan 40 mg QD
  • Atorvastatin 10 mg QD

Physical & lab evaluation

  • A1C: 8.1%
  • FPG: 118 mg/dL
  • PPG: 242 mg/dL
  • BMI: 33 kg/m2

Patient History

  • Duration of diabetes: 12 years.
  • A1C continues to rise despite more than 12 months of treatment with basal insulin plus an OAD.
  • Doctor prescribed using a CGM for 14 days and identified excursions in Lidia’s FPG and PPG levels.
  • Is determined to lower her A1C because of concerns about her blood glucose levels, which show considerable intra-day variability.
  • When considering new treatments, has concerns about hypoglycemia.

Insurance

  • PPO

   

LixiLan-L Post Hoc Subgroup Analysis

More Patients Who had A1C ≥9% Achieved ADA Goal (7% A1C) With SOLIQUA 100/333

Chart showing A1C reduction from baseline (9.45% Soliqua, 9.46% Lantus) to Week 30: Soliqua 6.97% (-1.45%) and Lantus 7.66% (-0.79%) in LixiLan-L Post Hoc Subgroup Analysis Study. The limitations include that the study is not designed or powered to detect differences between treatments within this subgroup; the difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.

This study was not designed or powered to detect differences between treatments within this subgroup. The difference in effect observed in this subgroup analysis may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.1

When A1C Is High, the ADA Recommends the Use of a Basal Insulin Plus GLP-1RA and or GLP-1RA + GIP RA to Get A1C down4

The 2026 ADA Guidelines recommend initial injectable combinations, such as basal insulin plus a GLP-1 RA, and or GLP-1RA + GIP RA when A1C is >1.5% - 2%.

   

Important Safety Information

Important Safety Information for SOLIQUA 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL

Contraindications

  • During episodes of hypoglycemia.
  • In patients with known serious hypersensitivity to insulin glargine, lixisenatide, or to any of the product components.

Warnings and Precautions

  • Anaphylaxis and Serious Hypersensitivity Reactions: In clinical trials of lixisenatide, there have been cases of anaphylaxis and other serious hypersensitivity reactions including angioedema. Severe, life threatening, generalized allergic reactions, including anaphylaxis and angioedema, can occur with insulins, including insulin glargine. There have been reports of serious hypersensitivity reactions, including anaphylactic reactions and angioedema, in patients treated with SOLIQUA 100/33. If hypersensitivity reactions occur, discontinue SOLIQUA 100/33. Use caution in patients with a history of anaphylaxis or angioedema with another glucagon-like peptide-1 (GLP-1) receptor agonist (RA) because it is unknown whether such patients will be predisposed to anaphylaxis.
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 RAs. After initiation of SOLIQUA 100/33, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue SOLIQUA 100/33 and initiate appropriate management.
  • Never Share a SOLIQUA 100/33 SoloStar® Pen between Patients: Pen-sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed.
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Changes should be made cautiously, and the frequency of blood glucose monitoring should be increased. Adjustments in concomitant oral antidiabetic treatment may be needed. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.
  • Medication Errors: SOLIQUA 100/33 contains two drugs. Do not administer more than 60 units of SOLIQUA 100/33, which may result in overdose of the lixisenatide component. Do not use other GLP-1 RAs. Accidental mix-ups between insulin products have been reported. Instruct patients to always check the label before administration. Do not withdraw SOLIQUA 100/33 from the pen with a syringe.
  • Hypoglycemia: Hypoglycemia is the most common adverse reaction associated with insulin-containing therapy, which may be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity, and in patients with renal or hepatic impairment and hypoglycemia unawareness.
  • Acute Kidney Injury Due to Volume Depletion: There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea. Monitor renal function in patients reporting adverse reactions to SOLIQUA 100/33 that could lead to volume depletion, especially during dosage initiation and escalation of SOLIQUA 100/33. SOLIQUA 100/33 is not recommended in patients with end-stage renal disease.
  • Severe Gastrointestinal Adverse Reactions: Use of GLP-1 receptor agonists, including SOLIQUA 100/33, has been associated with gastrointestinal adverse reactions, sometimes severe. SOLIQUA 100/33 is not recommended in patients with severe gastroparesis.
  • Immunogenicity: Patients may develop antibodies to insulin and lixisenatide. If there is worsening glycemic control or failure to achieve targeted glycemic control, significant injection site reactions or allergic reactions, then other antidiabetic therapy should be considered.
  • Hypokalemia: All insulin containing products can cause hypokalemia, which may be life-threatening. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk of hypokalemia and treat if indicated.
  • Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) and insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.
  • Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and post-marketing. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation: SOLIQUA 100/33 delays gastric emptying. There have been rare post marketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking SOLIQUA 100/33.

Most Common Adverse Reactions

The most common adverse reactions reported in ≥ 5% of patients treated with SOLIQUA 100/33 include hypoglycemia, nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, and headache.

Drug Interactions

  • Certain drugs may affect glucose metabolism, requiring dose adjustment of SOLIQUA 100/33 and close monitoring of blood glucose.
  • The signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (eg, betablockers, clonidine, guanethidine, and reserpine).
  • The lixisenatide in SOLIQUA 100/33 delays gastric emptying, which may reduce the rate of absorption of orally administered medication with a narrow therapeutic ratio or that require careful clinical monitoring. If such medications are to be administered with food, do not co-administer with SOLIQUA 100/33.
  • Antibiotics, acetaminophen, or other medications that are dependent on threshold concentrations for efficacy, or where a delay in effect is undesirable, should be administered at least 1 hour before SOLIQUA 100/33 injection.
  • Oral contraceptives should be taken at least 1 hour before SOLIQUA 100/33 administration or 11 hours after.

Indication

SOLIQUA 100/33 is a combination of insulin glargine, an insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use:

  • Concomitant use in combination with any other product containing a GLP-1 receptor agonist is not recommended.
  • Not recommended for the treatment of diabetic ketoacidosis.
  • Has not been studied in combination with prandial insulin.

Click here for full Prescribing Information.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

Important Safety Information

Indication

Abbreviations: ADA, American Diabetes Association; A1C, glycated hemoglobin; BID, twice per day; BMI, body mass index; CGM, continuous glucose monitor; FPG, fasting plasma glucose; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; OAD, oral antidiabetic drug; PPG, post-prandial glucose; QD, daily; QHS, every night at bedtime; RA, receptor agonist; SMPG, self-monitored plasma glucose; T2DM, type 2 diabetes mellitus.

References:

  1. SOLIQUA 100/33 Prescribing Information.

  2. Handelsman Y, Chovanes C, Dex T, et al. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019;33(3):236-242.

  3. Niemoeller E, Souhami E, Wu Y, Jensen KH. iGlarLixi reduces glycated hemoglobin to a greater extent than basal insulin regardless of levels at screening: post hoc analysis of LixiLan-L. Diabetes Ther. 2018;9:373-382.

  4. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49 (Suppl 1): S183-S215.

Soliqua and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2110931-v3.0-01/2026

Back to top
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContactAccessibility Statement
© 2026 Sanofi. All rights reserved.